Fenbendazole is an anti-worm medication that has been shown to have significant anti-tumor activity. It destroys the microtubules in cancer cells, which blocks their ability to take up glucose for energy. It also boosts the production of p53, a gene that cancer patients may lack. It is gaining interest after some famous sanare lab fenbendazole cancer success stories, including one from a man who was diagnosed with stage 4 small cell lung cancer and given only three months to live.
During facility treatment with fenbendazole (2018S, Harlan Teklad) for pinworm infestations at our institution, an established human lymphoma xenograft model failed to grow in C.B-17/Icr-prkdcscid/Crl (SCID) mice. It was determined that fenbendazole had contaminated the sterilizable diet that contained it and that supplemental vitamins used to compensate for loss during sterilization were added unautoclaved. This led to higher concentrations of vitamins than would normally be seen in a prepared diet. Upon re-establishing the xenografts, it was found that both fenbendazole and supplemental vitamins significantly inhibited tumor growth.
Initial complete blood counts showed a typical SCID leukocyte response dominated by neutrophils. At study termination, neutrophil counts were significantly smaller in the fenbendazole plus vitamin group than in controls, although initial white cell counts did not differ between groups. This observation suggests that the observed antitumor effects of fenbendazole and supplemented vitamins were the result of a synergistic effect rather than the direct action of each compound alone. The high concentrations of vitamins in the fenbendazole-supplemented diet may have contributed to the resulting antitumor effects. sanare lab fenbendazole